FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189784476> ?p ?o ?g. }

• W3189784476 endingPage "809" @default.
• W3189784476 startingPage "808" @default.
• W3189784476 abstract "Familial thrombocythaemia (FT) includes a group of predominantly autosomal dominant conditions due to various mutations in the thrombopoietin (THPO), myeloproliferative leukaemia virus oncogene (MPL), or Janus kinase 2 (JAK2) genes.1 These disorders differ from essential thrombocythaemia (ET), one of the classical, Philadelphia chromosome breakpoint cluster region-Abelson tyrosine-protein kinase 1 (BCR-ABL1)-negative myeloproliferative neoplasms (which are a group of diseases characterised by vascular and bleeding complications and risk of fibrotic or leukaemic transformation.) Of the three common drivers responsible for ET [JAK2, calreticulin (CALR) and MPL), MPL is responsible for <5% of ET cases.2, 3 In this issue, Al-Harbi et al.4 describe a cohort of 64 patients with familial thrombocythaemia due to four different MPL mutations. The cohort described in this paper is young, with a median age of 20 years (Table I) and approximately ˜40% of subjects being aged ≤14 years.4 While ET is the most common classical myeloproliferative neoplasm in young patients,5 it is classically a disease of older patients, with a median age in the 50’s.2 The median platelet count in this cohort was 707·5 × 109/l; two older cohorts of MPL-mutated ET patients had higher median counts (749 and 949 × 109/l).2, 3 The majority of patients in this cohort had the c.317C>T (Pro106Leu) mutation, which has previously been reported in patients with familial thrombocythaemia.2-4 Only one patient in this cohort had a thrombotic event, and this occurred after organ transplant. Thrombotic events have been reported in patients with familial thrombocythaemia harbouring the MPL Ser505Asn mutation.6 While there is a clear association between JAK2V617F mutation and thrombosis,7 the relationship between MPL mutations and thrombotic events is less well defined. Various series report rates of thrombosis in patients with MPL-mutated ET ranging from 0% to 40%.8 A portion of the patients in this cohort (11%) were treated with cytoreductive therapy with hydroxyurea, yet there are no clear guidelines for management of familial thrombocythaemia nor any data suggesting platelet count is associated with thrombotic risk. Management of ET is dependent on risk stratification, and cytoreductive therapy is generally not recommended in younger patients without JAK2V617F mutation and no other indications for cytoreduction (such as acquired von Willebrand disease or thrombosis).9 Alternatively, aspirin is often used for patients with ET with vascular symptoms, and 32% of this cohort received aspirin. While this paper was a retrospective analysis, it is reassuring that no patients were identified to have myelofibrotic or leukaemic progression. Development of marrow fibrosis and decreased survival has been reported in patients with familial thrombocythaemia and MPL Ser505Asn mutation.10 Progression to post-ET myelofibrosis or acute leukaemia has been reported in patients with MPL-mutated ET, and some series report poorer outcomes with MPL-mutated ET, which may be due to mischaracterisation of pre-myelofibrosis as ET.3 Given the difference in prognosis, it is important to distinguish between ET and FT. Obtaining a detailed family history and characterising the specific MPL mutation involved can help with this distinction, and when haematological complications or uncertainty are present, a bone marrow evaluation can help aid in the diagnosis of ET. One of the most interesting aspects of this cohort is the role of the tribal system and its relevance for genetic disease. There are numerous tribes in Saudi Arabia and tribal affiliation is often maintained through intra-tribal and intra-familial pairing.11 All of the patients in this cohort were members of only 26 tribes, and 48% of patients belonged to two tribes. While many forms of familial thrombocythaemia have autosomal dominant transmission, the authors suggest autosomal recessive transmission plays a role in this setting. More than half of the patients with MPL Pro106Leu were homozygous for the mutation, and autosomal recessive transmission has been previously suggested with this mutation.12 This is a large series of patients with familial thrombocythaemia and supports previous reports that for disease associated with many of the known MPL mutations there is a benign clinical course. Treatment with cytoreductive therapies involves potential risks and side-effects, and further insight into the clinical course of familial thrombocythaemia is important for physicians treating patients with these conditions. While management of vascular symptoms with aspirin when present is reasonable, reacting to the mere presence of thrombocythaemia with cytoreductive therapies does not seem appropriate or necessary. Nicole Kucine received support from a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) K23HL127223." @default.
• W3189784476 created "2021-08-16" @default.
• W3189784476 creator A5003759796 @default.
• W3189784476 creator A5062688748 @default.
• W3189784476 date "2021-08-02" @default.
• W3189784476 modified "2023-09-25" @default.
• W3189784476 title "Familial thrombocythaemia – a distinct entity from essential thrombocythaemia" @default.
• W3189784476 cites W1989920259 @default.
• W3189784476 cites W2054200299 @default.
• W3189784476 cites W2107367045 @default.
• W3189784476 cites W2618679305 @default.
• W3189784476 cites W2764282137 @default.
• W3189784476 cites W2809470681 @default.
• W3189784476 cites W2900973650 @default.
• W3189784476 cites W2907564353 @default.
• W3189784476 cites W2911450427 @default.
• W3189784476 cites W2992998099 @default.
• W3189784476 cites W3120811382 @default.
• W3189784476 cites W3166957787 @default.
• W3189784476 doi "https://doi.org/10.1111/bjh.17701" @default.
• W3189784476 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8500324" @default.
• W3189784476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34340263" @default.
• W3189784476 hasPublicationYear "2021" @default.
• W3189784476 type Work @default.
• W3189784476 sameAs 3189784476 @default.
• W3189784476 citedByCount "1" @default.
• W3189784476 countsByYear W31897844762021 @default.
• W3189784476 crossrefType "journal-article" @default.
• W3189784476 hasAuthorship W3189784476A5003759796 @default.
• W3189784476 hasAuthorship W3189784476A5062688748 @default.
• W3189784476 hasBestOaLocation W31897844761 @default.
• W3189784476 hasConcept C109159458 @default.
• W3189784476 hasConcept C126322002 @default.
• W3189784476 hasConcept C158617107 @default.
• W3189784476 hasConcept C170493617 @default.
• W3189784476 hasConcept C2777863708 @default.
• W3189784476 hasConcept C2778713057 @default.
• W3189784476 hasConcept C2780007613 @default.
• W3189784476 hasConcept C2780076729 @default.
• W3189784476 hasConcept C2781057849 @default.
• W3189784476 hasConcept C2781107747 @default.
• W3189784476 hasConcept C28328180 @default.
• W3189784476 hasConcept C2910274570 @default.
• W3189784476 hasConcept C32465701 @default.
• W3189784476 hasConcept C47450691 @default.
• W3189784476 hasConcept C54355233 @default.
• W3189784476 hasConcept C71924100 @default.
• W3189784476 hasConcept C72563966 @default.
• W3189784476 hasConcept C86803240 @default.
• W3189784476 hasConcept C89560881 @default.
• W3189784476 hasConcept C90924648 @default.
• W3189784476 hasConceptScore W3189784476C109159458 @default.
• W3189784476 hasConceptScore W3189784476C126322002 @default.
• W3189784476 hasConceptScore W3189784476C158617107 @default.
• W3189784476 hasConceptScore W3189784476C170493617 @default.
• W3189784476 hasConceptScore W3189784476C2777863708 @default.
• W3189784476 hasConceptScore W3189784476C2778713057 @default.
• W3189784476 hasConceptScore W3189784476C2780007613 @default.
• W3189784476 hasConceptScore W3189784476C2780076729 @default.
• W3189784476 hasConceptScore W3189784476C2781057849 @default.
• W3189784476 hasConceptScore W3189784476C2781107747 @default.
• W3189784476 hasConceptScore W3189784476C28328180 @default.
• W3189784476 hasConceptScore W3189784476C2910274570 @default.
• W3189784476 hasConceptScore W3189784476C32465701 @default.
• W3189784476 hasConceptScore W3189784476C47450691 @default.
• W3189784476 hasConceptScore W3189784476C54355233 @default.
• W3189784476 hasConceptScore W3189784476C71924100 @default.
• W3189784476 hasConceptScore W3189784476C72563966 @default.
• W3189784476 hasConceptScore W3189784476C86803240 @default.
• W3189784476 hasConceptScore W3189784476C89560881 @default.
• W3189784476 hasConceptScore W3189784476C90924648 @default.
• W3189784476 hasFunder F4320337338 @default.
• W3189784476 hasIssue "5" @default.
• W3189784476 hasLocation W31897844761 @default.
• W3189784476 hasLocation W31897844762 @default.
• W3189784476 hasLocation W31897844763 @default.
• W3189784476 hasOpenAccess W3189784476 @default.
• W3189784476 hasPrimaryLocation W31897844761 @default.
• W3189784476 hasRelatedWork W1979275941 @default.
• W3189784476 hasRelatedWork W2045494967 @default.
• W3189784476 hasRelatedWork W2130526081 @default.
• W3189784476 hasRelatedWork W2143977369 @default.
• W3189784476 hasRelatedWork W2157694607 @default.
• W3189784476 hasRelatedWork W2945090381 @default.
• W3189784476 hasRelatedWork W3003967832 @default.
• W3189784476 hasRelatedWork W3109812984 @default.
• W3189784476 hasRelatedWork W3189784476 @default.
• W3189784476 hasRelatedWork W4214608384 @default.
• W3189784476 hasVolume "194" @default.
• W3189784476 isParatext "false" @default.
• W3189784476 isRetracted "false" @default.
• W3189784476 magId "3189784476" @default.
• W3189784476 workType "article" @default.